Bionano Genomics Inc (BNGO)vsMedline Inc. Class A Common Stock (MDLN)
BNGO
Bionano Genomics Inc
$1.22
+1.67%
HEALTHCARE · Cap: $14.37M
MDLN
Medline Inc. Class A Common Stock
$32.53
+0.43%
HEALTHCARE · Cap: $43.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 99115% more annual revenue ($29.94B vs $30.18M). MDLN leads profitability with a 2.3% profit margin vs -106.6%. MDLN earns a higher WallStSmart Score of 52/100 (C-).
BNGO
Hold39
out of 100
Grade: F
MDLN
Buy52
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Earnings expanding 262.0% YoY
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -84.3% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
2.3% margin — thin
Operating margin of 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BNGO
The strongest argument for BNGO centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 21.4% demonstrates continued momentum.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : BNGO
The primary concerns for BNGO are EPS Growth, Market Cap, Return on Equity.
Bear Case : MDLN
The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.6x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
BNGO profiles as a growth stock while MDLN is a value play — different risk/reward profiles.
BNGO is growing revenue faster at 21.4% — sustainability is the question.
MDLN generates stronger free cash flow (604M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 39/100) and 11.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bionano Genomics Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.
Visit Website →Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?